A new method to remove HIV-infected cells from the body
A new strategy to eliminate HIV-1-infected cells by unlocking the Env trimer
This study is working on new antibodies that can help your body fight HIV by targeting and destroying infected cells, with the hope of creating better treatments for people living with the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10900611 on NIH RePORTER |
What this research studies
This research focuses on developing engineered antibodies that target specific parts of the HIV virus to help eliminate infected cells. By creating antibodies that can effectively recognize and attack these cells, the study aims to enhance the body's immune response against HIV. The approach involves using therapeutic antibodies that are designed to work better in the presence of HIV-infected plasma, potentially leading to more effective treatments for individuals living with HIV. The research builds on previous successes in antibody development and aims to create a new class of treatments that could significantly reduce the viral reservoir in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who have not achieved viral suppression with current therapies.
Not a fit: Patients who are not infected with HIV-1 or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially allowing for the elimination of the virus from the body.
How similar studies have performed: Other research has shown promise in using engineered antibodies for HIV treatment, indicating that this approach has potential based on previous successes.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Pazgier, Marzena Elzbieta — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Pazgier, Marzena Elzbieta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.